In conclusion, our findings go beyond the understanding of how FH mutations lead to HLRCC and pave the way for the understanding of how mitochondrial metabolites could promote tumorigenesis. This evidence concerns the gene FH and hereditary leiomyomatosis and renal cell cancer.